dc.contributor.author | Allott, L | |
dc.contributor.author | Da Pieve, C | |
dc.contributor.author | Meyers, J | |
dc.contributor.author | Spinks, T | |
dc.contributor.author | Ciobota, DM | |
dc.contributor.author | Kramer-Marek, G | |
dc.contributor.author | Smith, G | |
dc.date.accessioned | 2017-07-20T11:26:16Z | |
dc.date.issued | 2017-07-27 | |
dc.identifier.citation | Chemical communications (Cambridge, England), 2017, 53 (61), pp. 8529 - 8532 | |
dc.identifier.issn | 1359-7345 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/736 | |
dc.identifier.eissn | 1364-548X | |
dc.identifier.doi | 10.1039/c7cc03572a | |
dc.description.abstract | The future of 89Zr-based immuno-PET is reliant upon the development of new chelators with improved stability compared to the currently used deferoxamine (DFO). Herein, we report the evaluation of the octadentate molecule DFO-HOPO (3) as a suitable chelator for 89Zr and a more stable alternative to DFO. The molecule showed good potential for the future development of a DFO-HOPO-based bifunctional chelator (BFC) for the radiolabelling of biomolecules with 89Zr. This work broadens the selection of available chelators for 89Zr in search of improved successors to DFO for clinical 89Zr-immuno-PET. | |
dc.format | Print | |
dc.format.extent | 8529 - 8532 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | ROYAL SOC CHEMISTRY | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.title | Evaluation of DFO-HOPO as an octadentate chelator for zirconium-89. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2017-07-07 | |
rioxxterms.versionofrecord | 10.1039/c7cc03572a | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2017-07 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Chemical communications (Cambridge, England) | |
pubs.issue | 61 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicinal Chemistry 1 | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Preclinical Molecular Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Closed research teams | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Closed research teams/PET Radiochemistry | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Preclinical Molecular Imaging | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicinal Chemistry 1 | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Preclinical Molecular Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Closed research teams | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Closed research teams/PET Radiochemistry | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Preclinical Molecular Imaging | |
pubs.publication-status | Published | |
pubs.volume | 53 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Medicinal Chemistry 1 | |
icr.researchteam | PET Radiochemistry | |
icr.researchteam | Preclinical Molecular Imaging | |
dc.contributor.icrauthor | Da Pieve, Chiara | |
dc.contributor.icrauthor | Kramer-Marek, Gabriela | |
dc.contributor.icrauthor | Smith, Graham | |